Table 3.
Barriers to prescribing PrEP therapy (n, %).
| Barrier | Strongly Agree | Agree | Neutral | Disagree | Strongly Disagree |
|---|---|---|---|---|---|
| Limited or no knowledge of PrEP guidelines (n = 17) | 8 (47%) | 4 (24%) | 4 (24%) | 1 (6%) | 0 (0%) |
| Concerned about side effects of Truvada as a prophylactic medication (n = 17) | 1 (6%) | 3 (18%) | 11 (65%) | 2 (12%) | 0 (0%) |
| PreP therapy could increase the likelihood of sexually transmitted infections among men who have sex with men (n = 17) | 1 (6%) | 1 (6%) | 7 (41%) | 6 (35%) | 2 (12%) |
| There are patient adherence and compliance issues with PrEP that will decrease its efficacy (n = 17) | 0 (0%) | 5 (29%) | 8 (47%) | 3 (18%) | 1 (6%) |
| Prescribing will increase high risk sexual behaviors among men who have sex with men (n = 17). | 1 (6%) | 1 (6%) | 5 (29%) | 7 (41%) | 3 (18%) |
| PrEP therapy will decrease safe sex practices among men who have sex with men (n = 17) | 1 (6%) | 3 (18%) | 4 (24%) | 8 (47%) | 1 (6%) |
| There would be a stigma or backlash in the office if I prescribe PrEP therapy (n = 17) | 1 (6%) | 0 (0%) | 3 (18%) | 11 (65%) | 2 (12%) |
| Limited time or resources for patient education about PrEP therapy (n = 17) | 1 (6%) | 6 (35%) | 8 (47%) | 2 (12%) | 0 (0%) |
| No desire to prescribe a medication that requires lab work and follow up every 3 months (n = 17) | 0 (0%) | 3 (18%) | 9 (53%) | 4 (24%) | 1 (6%) |
| Perceived moral and/or ethical dilemma prescribing PrEP to men who have sex with men (n = 16) | 0 (0%) | 2 (13%) | 3 (19%) | 8 (50%) | 3 (19%) |